Telesis Bio, Inc. (TBIO)

Market Cap	674.82K
Revenue (ttm)	17.03M
Net Income (ttm)	-47.93M
Shares Out	1.78M
EPS (ttm)	-28.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,900
Open	0.390
Previous Close	0.420
Day's Range	0.380 - 0.420
52-Week Range	0.346 - 15.460
Beta	1.76
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 20, 2025

About Telesis Bio

Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an in...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2011
• Employees: 147
• Stock Exchange: OTCMKTS
• Ticker Symbol: TBIO

Financial Performance

In 2023, Telesis Bio's revenue was $27.51 million, an increase of 0.27% compared to the previous year's $27.44 million. Losses were -$49.02 million, 1.14% more than in 2022.